Posaconazole-induced hypertension in children with cystic fibrosis.

Authors :: Marpole R
Yeoh DK
Withers AL
Source :: Respirology case reports [Respirol Case Rep] 2021 Aug 04; Vol. 9 (9), pp. e0822. Date of Electronic Publication: 2021 Aug 04 (Print Publication: 2021).
Publication Year :: 2021
Abstract: Posaconazole is a triazole antifungal with a broad spectrum of activity against moulds including Aspergillus spp. Emerging data suggest posaconazole may be effective in the treatment of allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis (CF). Rarely, posaconazole can cause pseudohyperaldosteronism, manifesting as hypertension and electrolyte abnormalities, with a number of cases recently reported in individuals without CF. We describe two cases of children with CF who developed hypertension, likely due to pseudohyperaldosteronism, following the initiation of posaconazole for the treatment of ABPA.<br />Competing Interests: None declared.<br /> (© 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.)